Business
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover F
About this update from Voyager Acquisition Corp
[{"type":"list","items":[{"val":[{"type":"text","content":"VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical Profiles","length":280,"tagName":"p"}]},{"val":[{"type":"text","content":"Company Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Transaction Values VERAXA at a Pre-money Equity Value of $1.3 Billion","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Actively Working with Existing and New VERAXA Investors to Raise a Crossover Financing Round, which is Expected to Close Ahead of the Business Combination, Alongside up to $253 Million in Cash Held in Trust","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Business Combination is Expected to be Completed in the Fourth Quarter of 2025","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"A Joint Investor Presentation Providing an Overview of the Proposed Transaction can be Viewed: https://dealroadshow.com/e/VER2025","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":855,"olType":false},{"type":"text","content":"ZURICH, Switzerland, and BROOKLYN, New York, April 23, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, “Voyager” or the “SPAC”), announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement"). The proposed business combination (the "Business Combination") would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”","length":858,"tagName":"p"},{"type":"text","content":"VERAXA Overview","length":15,"tagName":"p"},{"type":"text","content":"VERAXA is advancing a premier drug discovery and ...